Form 4: Aura Biosciences CFO Anthony Gibney Receives Significant Equity Awards

Aura Biosciences, Inc.'s Chief Financial and Business Officer, Anthony S. Gibney, was granted 150,000 restricted stock units and 250,000 stock options, aligning his interests with the company's long-term performance.

Summary

• Anthony S. Gibney, Chief Financial and Business Officer of Aura Biosciences, Inc. (AURA), reported the acquisition of 150,000 shares of Common Stock through a Restricted Stock Unit (RSU) award on June 2, 2025.
• These RSUs were granted at a price of $0 per share and represent the right to receive one share of Common Stock for each RSU.
• The RSU award vests in four substantially equal annual installments, commencing on June 15, 2026, contingent upon Mr. Gibney's continued service.
• Additionally, Mr. Gibney was granted 250,000 stock options on June 2, 2025, with an exercise price of $6.16 per share and an expiration date of June 2, 2035.
• The stock options vest 25% on May 13, 2026, with the remaining portion vesting pro-rata in 36 monthly installments thereafter, also subject to continued service.
• Following these transactions, Mr. Gibney beneficially owns 206,933 shares of Common Stock and 250,000 stock options.

Sentiment

Score: 7

Explanation: The sentiment is positive as the equity grants align the interests of a key executive with shareholders, incentivizing long-term performance and retention. This is a standard and generally well-received form of executive compensation.

Positives

• The grant of significant equity awards (RSUs and stock options) to a key executive like the CFO aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• The vesting schedules for both the RSUs and stock options encourage continued service and commitment from the Chief Financial and Business Officer.

Future Outlook

The vesting schedules for the RSU and stock option awards extend several years into the future, indicating an expectation of continued service from the Chief Financial and Business Officer and a long-term incentive structure tied to the company's performance.

Management Comments

• The equity awards were granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan, reflecting a standard compensation practice.

Industry Context

The granting of restricted stock units and stock options is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. This aligns the executive's financial success with the company's long-term growth and shareholder value creation, which is particularly relevant in industries with long development cycles and high R&D costs.

Comparison to Industry Standards

• The structure of these equity grants, including vesting over several years and a mix of RSUs and stock options, is consistent with typical executive compensation packages observed in comparable biotechnology companies.
• The use of a pre-existing '2021 Stock Option and Incentive Plan' indicates a formalized and approved compensation framework, common among publicly traded companies.

Corporate Governance

Related Party Transactions

• The acquisition of 150,000 restricted stock units and 250,000 stock options by Anthony S. Gibney, an officer of Aura Biosciences, Inc., constitutes a related party transaction as it involves compensation from the company to a key executive.

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of executive interests with shareholder value creation through performance-based equity awards.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, potentially boosting morale.

Next Steps

• Continued service of Anthony S. Gibney to meet vesting conditions for both RSU and stock option awards.
• Future disclosures of any changes in beneficial ownership by Anthony S. Gibney as required by Section 16(a) of the Securities Exchange Act of 1934.

Key Dates

Keywords

Aura Biosciences, AURA, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Award, Executive Compensation, Anthony S. Gibney, CFO